FDA Grants Orphan Drug Status to Trillium’s TTI-621 for Cutaneous T-Cell Lymphoma
News
TTI-621, an investigational molecule developed by Trillium that turns macrophages against tumor cells, was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. ... Read more